Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

BACKGROUND: Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory. Prenylation is essential for HDV and inhibition abrogates HDV production in experimental models. In a proof-of-concept study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the p...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Infect Dis
Main Authors: Koh, Christopher, Canini, Laetitia, Dahari, Harel, Zhao, Xiongce, Uprichard, Susan L, Haynes-Williams, Vanessa, Winters, Mark A, Subramanya, Gitanjali, Cooper, Stewart L, Pinto, Peter, Wolff, Erin F, Bishop, Rachel, Han, Ma Ai Thanda, Cotler, Scott J, Kleiner, David E, Keskin, Onur, Idilman, Ramazan, Yurdaydin, Cihan, Glenn, Jeffrey S, Heller, Theo
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4700535/
https://ncbi.nlm.nih.gov/pubmed/26189433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(15)00074-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki